<DOC>
	<DOCNO>NCT02488629</DOCNO>
	<brief_summary>To evaluate safety efficacy SCB01A head neck cancer .</brief_summary>
	<brief_title>Study SCB01A Patient With Head Neck Cancer</brief_title>
	<detailed_description>The study design evaluate safety efficacy SCB01A patient recurrent metastatic squamous cell carcinoma head neck .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Confirmed squamous cell carcinoma head neck 2 . Patients nonresectable , unfeasible radiotherapy , recurrent metastatic carcinoma , previous treatment platinum agent . 3 . At least one measurable tumor lesion accord RECIST 4 . Suitable Eastern Cooperative Oncology Group ( ECOG ) performance status 5 . All eligible patient childbearing potential use effective contraception 6 . Signed informed consent enrolment 1 . Receiving Chemotherapy , radiation therapy , major surgery investigational agent 2 . Severe pulmonary obstructive restrictive disease 3 . Uncontrolled inflammatory disease 4 . Clinically significant cardiac disease 5 . Results laboratory test 6 . Pregnancy nursing status 7 . Known hypersensitivity component SCB01A 8 . History exposure SCB01A analogues 9 . History malignancy head neck cancer 10 . History active significant neurological disorder psychiatric disorder 11 . Any reason investigator deem patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Head neck squamous cell carcinoma</keyword>
</DOC>